RxDoctor Payments Data

Anna Greene

Nurse Practitioner · Montgomery, ALNPI 1821527615

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 108 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seapearl East, Inc$1K
  • Novartis$354
  • Actelion Pharmaceuticals US, Inc.$262
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$192
  • E.r. Squibb & Sons, L.L.C.$160
  • Pfizer$150
  • plus $944 from 13 others

What the payments were for

  • Food & beverage$2,05663%
  • Education$1,20537%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,261 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$48,612
Medicare patients
448
Services billed
956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$134,041
EntrestoSacubitril/Valsartan119$114,862
FarxigaDapagliflozin Propanediol40$30,488
MultaqDronedarone Hcl23$28,279
XareltoRivaroxaban11$15,184
BrilintaTicagrelor12$7,157
Metoprolol Succinate237$5,390
Ranolazine ErRanolazine23$2,739
Carvedilol174$2,087
Flecainide Acetate45$1,786
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$1,658
Isosorbide Mononitrate ErIsosorbide Mononitrate94$1,457
Atorvastatin Calcium105$1,434
Potassium Chloride64$1,377
Losartan Potassium112$1,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$150$134,041141 claims
NovartisEntresto$354$114,862119 claims
AstraZenecaFarxiga, Brilinta$131$37,64552 claims
Sanofi-aventis U.S. LLCMultaq$112$28,27923 claims
Johnson & JohnsonXarelto$100$15,18411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →